Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Industry (Medical Devices)

Industry (Medical Devices)

                        Letters to Industry
          Send and Track Medical Device Premarket Submissions Online: CDRH Portal Home
          Medical Devices
          Resources for You (Medical Devices)
          Industry (Medical Devices)
          Studies Using Leftover, Deidentified Human Specimens Require IRB Review – Letter to IndustryIndustry (Medical Devices) Studies Using Leftover, Deidentified Human Specimens Require IRB Review – Letter to Industry
  
  	
    Share
    Post
    Linkedin

    Email
    PrintOctober 18, 2021

Dear In Vitro Diagnostic Manufacturers,

The U.S. Food and Drug Administration (FDA) is reminding the diagnostic device industry that we require Institutional Review Board (IRB) review for all clinical investigations of devices that involve human subjects, including those that use leftover, deidentified human specimens in FDA-regulated studies. This requirement pertains to data used to support an investigational device exemption, device marketing application, or submission to the FDA, including in vitro diagnostic (IVD) technical or analytical studies that use human specimens. For further explanation, see the Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Devices 2018 final rule.

The 2006 FDA guidance, Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable, does **not** exempt any investigations from IRB requirements. The guidance states that we intend to exercise enforcement discretion with regard to the requirements for informed consent under the circumstances described in Section IV of the guidance. The FDA issued the guidance to help reduce obstacles for IVD device development and to facilitate development consistent with Good Clinical Practices (GCP) and Clinical Trials. However, the guidance expressly states that for those clinical investigations in which we intend to exercise enforcement discretion for informed consent, the requirement for IRB review in accordance with 21 CFR Part 56 remains.

Conformity with GCP is important and required for all clinical investigations, including investigations of IVD devices, to help ensure the data and results from clinical investigations are credible and accurate, and the rights, safety, and wellbeing of human subjects are adequately protected.

For more information, including information about data from investigations conducted inside or outside of the United States, please see Good Clinical Practice Requirements for Data Submitted from Clinical Investigations for In Vitro Diagnostic Device Premarket Submissions.



Sincerely,

William Maisel, MD, MPH
Director, Office of Product Evaluation and Quality
Center for Devices and Radiological Health
U.S. Food and Drug Administration

                                                                                  Content current as of:
      10/18/2021
              
              
Regulated Product(s)
		 Medical DevicesIndustry (Medical Devices)

          
                        Letters to Industry
          Send and Track Medical Device Premarket Submissions Online: CDRH Portal
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop